Biomedical Engineering

Kyriacos Athanasiou Named to Histogenics Scientific Advisory Board

Distinguished Professor and Chair Kyriacos Athanasiou

Kyriacos Athanasiou has been named to the Scientific Advisory Board of Histogenics Corporation. Histogenics Corporation, a privately held regenerative medicine company, is advancing NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure.

“This advisory board represents some of the most prolific researchers,publishers and innovators in regenerative medicine with an extensive range of expertise in cartilage and soft-tissue repair, biomaterial scaffolds, fibroblast growth factor variants and stem cell research,” said Patrick O’Donnell, President and Chief Executive Officer of Histogenics. “Each member will play a critical role in guiding our research and product development pipeline initiatives, including our next generation NeoCart On-Demand™ single step cartilage tissue implant, as we continue to build Histogenics’ leadership position in articular cartilage and soft tissue regeneration.”